^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MUC19 mutation

    i
    Other names: Mucin 19, Oligomeric, Mucin-19, MUC-19, FLJ35746, MUC19
    Entrez ID:
    283463
    over3years
    Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. (PubMed, Front Immunol)
    ICIs of Sintilimab were then used to target programmed death 1 (200mg i.v., Q3W) for up to 10 cycles...These preliminary findings exhibit the prospects in performing neoadjuvant or adjuvant immunotherapies on patients with sMPLC. https://www.chictr.org.cn/showproj.aspx?proj=36878, identifier ChiCTR1900022159.
    Journal • IO biomarker
    |
    MUC19 (Mucin 19, Oligomeric)
    |
    MUC19 mutation
    |
    Tyvyt (sintilimab)
    almost4years
    Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach. (ASCO 2022)
    MUC19 may be a potential target for HAS diagnosis and treatment. Amplification of genes located in chr19q12 occurred frequently in HAS and were associate with poor prognosis. TMB was sensitive for the overall survival of HAS patients.
    Tumor Mutational Burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CCNE1 (Cyclin E1) • AFP (Alpha-fetoprotein) • TTN (Titin) • MUC19 (Mucin 19, Oligomeric)
    |
    TP53 mutation • TMB-H • CCNE1 amplification • MUC19 mutation